Director Chan Galbato of Accuray Inc filed a statement of changes in beneficial ownership on November 17, 2026, reporting the vesting of restricted stock units on November 13, 2026.

Key Highlights

  • Reporting person: Chan Galbato, identified as a Director of Accuray Inc (NASDAQ:ARAY).
  • Transaction date: November 13, 2026, when 1,415 restricted stock units vested 100% and were acquired as common stock at a price of $0.
  • Resulting ownership: Galbato directly beneficially owned 2,665 shares of common stock following the transaction, according to the filing.
  • Reverse stock split: The filing discloses that on November 9, 2026, Accuray's common stock underwent a 1-for-40 reverse split, and beneficially owned shares were adjusted to reflect this change.
  • RSU structure: Each restricted stock unit represented a contingent right to receive one share of Accuray common stock, per the filing's footnote.
  • Filing signatory: The form was signed by Michael Stetler as Power of Attorney for Chan Galbato, dated November 17, 2026.

Accuray Director Galbato Reports RSU Settlement After Reverse Split

According to the filing, Chan Galbato, a director of Accuray Inc, reported the acquisition of 1,415 shares of common stock on November 13, 2026, through the vesting of restricted stock units. The transaction code recorded is "M," reflecting an exercise or conversion of derivative securities. The price attributed to the acquisition was $0, consistent with a standard RSU settlement where no cash consideration is paid by the recipient.

The filing also discloses a significant capital structure event at Accuray: on November 9, 2026, the company completed a 1-for-40 reverse stock split of its common stock. The filing states that "beneficially owned shares have been adjusted to reflect the reverse split," meaning the post-transaction ownership figure of 2,665 shares directly held by Galbato already incorporates that adjustment. Accuray Inc, listed on NASDAQ under the ticker ARAY, develops and commercializes radiation therapy systems used in oncology treatment. The RSU that vested was described in the filing as one that "vests 100% on 11/13/2026," indicating a cliff-vesting schedule for this particular award.

The form was filed by one reporting person, and there is no indication of an amendment to a prior filing. The derivative securities table shows that following the vesting transaction, the remaining balance of derivative securities beneficially owned by Galbato is zero, reflecting full settlement of this RSU grant.

What Was Disclosed

The filing reports Director Chan Galbato's acquisition of 1,415 Accuray common shares through RSU vesting on November 13, 2026, at no cost, resulting in direct beneficial ownership of 2,665 shares, adjusted for a 1-for-40 reverse stock split completed November 9, 2026.